Clinical Trials Logo
  1. Home
  2. Arteriovenous Graft
  3. NCT01928498

Drug Eluting Balloon for Prevention of Hemodialysis Access Restenosis — DEB  

Arteriovenous Graft Clinical Trial

Official title:
Evaluation of Drug Eluting Balloon for the Prevention of Hemodialysis Access Restenosis: A Prospective Randomized Trial (DEB Study)

Clinical Trial Summary

The purpose of this study is to evaluate the effectiveness of paclitaxel-coated balloon catheter to prevent restenosis after PTA (percutaneous transluminal angioplasty) of hemodialysis access (HA) in comparison with the uncoated PTA balloon catheter.

Clinical Trial Description

In Canada, there are over 20,000 patients with chronic end-stage renal disease (ESRD)on long-term hemodialysis and the number is increasing rapidly.The creation of hemodialysis access (HA) (also called "lifeline" for dialysis patients) has become the most common type of vascular surgery. These HA are frequently complicated by dysfunction after their creation mainly due to neointimal hyperplastic stenosis (> 60% at one year). PTA is an established cornerstone method of treating stenotic lesions because of its minimally invasive percutaneous nature and widespread availability.Although PTA has a high initial success rate,narrowing will often recur in 2-3 months hence requiring further interventions. There are currently no durable therapies for the prevention or treatment of HA dysfunction restenosis after PTA. Recently drug eluting balloon (DEB) with paclitaxel have repeatedly demonstrated their effectiveness to prevent restenosis due to intimal proliferation in the coronary and peripheral arterial systems. The investigators believe that the DEB with paclitaxel will significantly decrease the HA restenosis rate at the treated site and therefore will improve the management of HA failures. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01928498
Study type Interventional
Source Centre hospitalier de l'Université de Montréal (CHUM)
Contact
Status Completed
Phase N/A
Start date October 2013
Completion date August 27, 2020
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT03538392 - Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
Terminated NCT03668002 - Trial of Fistula Versus Graft in Elderly Patients N/A
Recruiting NCT05616104 - FLEX FIRST Registry Research Protocol
Recruiting NCT03360279 - DCB for Dialysis Access Stent Graft Restenosis N/A
Terminated NCT01806584 - An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Placement of an Arteriovenous Graft to Facilitate Hemodialysis Access Phase 2
Terminated NCT03300024 - Bovine Carotid Artery Biologic Graft and Expanded Polytetrafluoroethylene for Permanent Hemodialysis Access N/A
Completed NCT02331030 - A Randomised Trial Comparing Supraclavicular Block vs Supraclavicular and Pecs II Block in Arteriovenous Grafting N/A
Terminated NCT04017910 - Automated 3D Ultrasound-based Surveillance of Arteriovenous Fistula Maturation for Post-operative Hemodialysis Patients
Recruiting NCT05911451 - Optimizing Access Surgery In Senior Hemodialysis Patients N/A
Completed NCT00368147 - Access Creation for Hemodialysis: Association With Structural Changes of the Heart
Active, not recruiting NCT04796558 - Validation of Arterio Venous Access Stage (AVAS) Classification